Bulletin
Investor Alert

press release

Feb. 11, 2021, 4:01 p.m. EST

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

SAN FRANCISCO, Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. /zigman2/quotes/214486077/composite VIR +2.98% today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021.

The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio .

About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio .







        Contact:
        Cara Miller
        VP, Corporate Communications
        cmiller@vir.bio
        +1-415-941-6746
        


COMTEX_380695528/2471/2021-02-11T16:01:05

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 46.38
+1.34 +2.98%
Volume: 462,525
April 16, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$5.76 billion
Rev. per Employee
$233,541
loading...

Partner Center

Link to MarketWatch's Slice.